The Life Sciences team advised Corvidia Therapeutics on its definitive agreement to be acquired by Novo Nordisk A/S. Under the terms of the agreement, Novo Nordisk will acquire all outstanding shares of Corvidia Therapeutics for an upfront payment of 725 million US dollars in cash. Total payments to Corvidia Therapeutics shareholders could ultimately amount to 2.1 billion US dollars in cash upon the achievement of certain regulatory and sales milestones by Novo Nordisk.

Corvidia is a privately held, clinical stage company focused on the research and development of transformative therapies for cardio-renal diseases. Corvidia’s lead candidate, ziltivekimab, a fully human monoclonal antibody directed against Interleukin 6 (IL-6), is being developed to reduce the risk of major adverse cardiovascular events in chronic kidney disease patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation.

The Goodwin team was led by Courtney Hetrick, Kingsley Taft, Noelle Dubiansky, Yasin Akbari, and Kimberly Larie, and included Paul Jin, Dan Karelitz, Alex Apostolopoulos, Sarah Bock, James Devendorf, Ariel Gaknoki, Brad Smith, Caroline Galiatsos, Julie Tibbets, and Jacob Osborn.

For more details, read the press release and articles in The Boston Globe, Endpoints, and Reuters.